FY2026 EPS Estimates for Ardelyx, Inc. Increased by HC Wainwright (NASDAQ:ARDX)

• 3 mid-caps under $20 that Wall Street loves

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Ardelyx in a research note issued on Wednesday, July 3rd. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of $0.68 for the year, up from their previous forecast of $0.58. The consensus estimate for Ardelyx's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Ardelyx's FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.65 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $46.00 million for the quarter, compared to analyst estimates of $36.40 million. Ardelyx had a negative net margin of 41.36% and a negative return on equity of 41.65%. The business's quarterly revenue was up 303.5% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS.

• Is Ardelyx is A Buy After Slip in Early 2022

ARDX has been the subject of several other research reports. Piper Sandler downgraded Ardelyx from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $15.00 to $7.00 in a research report on Tuesday, July 2nd. Leerink Partnrs reaffirmed an "outperform" rating on shares of Ardelyx in a report on Friday, April 5th. StockNews.com cut Ardelyx from a "hold" rating to a "sell" rating in a research note on Friday, June 28th. SVB Leerink initiated coverage on Ardelyx in a research report on Friday, April 5th. They issued an "outperform" rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Ardelyx in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.31.

Check Out Our Latest Report on ARDX

Ardelyx Stock Performance

NASDAQ ARDX opened at $5.29 on Monday. Ardelyx has a twelve month low of $3.16 and a twelve month high of $10.13. The company has a quick ratio of 4.36, a current ratio of 4.53 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.23 billion, a P/E ratio of -18.89 and a beta of 0.83. The company's 50-day simple moving average is $6.93 and its 200 day simple moving average is $7.61.

Hedge Funds Weigh In On Ardelyx

Large investors have recently modified their holdings of the business. HighMark Wealth Management LLC acquired a new stake in Ardelyx during the first quarter worth approximately $36,000. Newbridge Financial Services Group Inc. bought a new position in Ardelyx in the first quarter worth approximately $64,000. SJS Investment Consulting Inc. bought a new position in shares of Ardelyx in the 4th quarter worth $62,000. Jump Financial LLC acquired a new stake in Ardelyx in the 4th quarter valued at $63,000. Finally, Paloma Partners Management Co acquired a new position in Ardelyx during the first quarter worth $86,000. Institutional investors own 58.92% of the company's stock.

Insider Buying and Selling

In other Ardelyx news, insider David P. Rosenbaum sold 17,872 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $7.00, for a total value of $125,104.00. Following the transaction, the insider now directly owns 158,502 shares of the company's stock, valued at approximately $1,109,514. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Ardelyx news, insider Robert Blanks sold 38,000 shares of the firm's stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $5.96, for a total value of $226,480.00. Following the sale, the insider now owns 324,331 shares in the company, valued at $1,933,012.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David P. Rosenbaum sold 17,872 shares of the company's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $7.00, for a total transaction of $125,104.00. Following the transaction, the insider now owns 158,502 shares of the company's stock, valued at $1,109,514. The disclosure for this sale can be found here. Insiders have sold 534,119 shares of company stock valued at $4,117,225 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

Read More

• Five stocks we like better than Ardelyx
• Insider Selling Explained: Can it Inform Your Investing Choices?
• MarketBeat Week in Review – 7/1 - 7/5
• What Does Downgrade Mean in Investing?
• Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
• How is Compound Interest Calculated?
• Qualcomm Stock Continues to Rise in the Face of Negative News

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Obama wins Presidential debate (From Porter & Company) (Ad)

Should you invest $1,000 in Ardelyx right now?

Before you consider Ardelyx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.

While Ardelyx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here